DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Comparison of Two Different Dosages of Low-molecular Weight Heparin in Cancer Patients

Information source: Medical University of Vienna
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Cancer

Intervention: enoxaparin (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Medical University of Vienna

Official(s) and/or principal investigator(s):
Sabine Eichinger, MD, Principal Investigator, Affiliation: Medical University of Vienna


In a prospective, randomized, double-blind trial, the effects of two different dosages of LMWH (5000 anti-Xa U od sc and 10 000 anti-Xa U od sc daily) on markers of hemostatic system and thrombin generation will be investigated in non-surgical cancer patients will be investigated.

Clinical Details

Official title: Prevention of Venous Thrombosis in Cancer Patients: A Prospective, Randomized, Double-blind Study Comparing Two Different Dosages of Low-molecular Weight Heparin

Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind


Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria: Patients (> 18 years) with active cancer and at least one of the following indications for thromboprophylaxis with LMWH:

- Immobilization

- History of VTE

- Acute inflammation

- Heart failure (NYHA class III or IV)

- Respiratory failure

Exclusion Criteria:

- Indication for LMWH or UFH at therapeutic dosages

- Treatment with antithrombotics (vitamin K antagonists, acetylsalicylic acid,

clopidogrel) for reasons other than prevention of VTE (e. g. atrial fibrillation, myocardial infarction)

- Contraindication for the treatment with LMWH

- Major surgery within the last 4 weeks; minor surgery within the last week

- Thrombocytopenia (< 100. 000/μl)

- Prolonged prothrombin time

- Prolonged activated partial thromboplastin time (aPTT)

- History of heparin-induced thrombocytopenia

- Bodyweight < 50 kg or > 100 kg

- Renal insufficiency (creatinine > 2 mg/dl)

Locations and Contacts

Medical University of Vienna, Vienna 1090, Austria
Additional Information

Starting date: June 2006
Last updated: September 17, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017